IDIBELL té una àmplia cartera de projectes innovadors en diferents estats de maduresa. Aquí trobaràs alguns dels nostres projectes que es troben en estat "màrqueting actiu" per als que busquem col·laboracions amb la indústria i possibles llicenciataris. El portafolis d'innovació de l'IDIBELL conté més de 150 projectes translacionals en les diferents àrees de recerca de l'IDIBELL. A més estem oberts a noves col·laboracions promogudes per la indústria.
PURPOSE: C4BP-based biologics as novel immunomodulators
Aran J. M. (IDIBELL)
An attempt to restore the immune homeostasis from patients suffering from immune-inflammatory processes such as GvHD, autoimmune diseases and transplant rejection. This physiological immunomodulator overcomes the side effects of the present immunosuppressive and anti-inflammatory drugs, and enables to perform pharmacological therapy.
New target Therapy for Triple Negative Breast Cancer
Eva González-Suárez (IDIBELL)
New strategy to inhibit RANK pathway for the treatment of TNBC. RANK is expressed in 40% of TNBC where it was linked with poor clinical outcomes. Cost-effective therapy for TNBC and NSCLC easing the economic burden
An Endo-Luminal Linear Anastomosis (ELLA) Stapler
Golda T (IDIBELL, HUB)
A new device for endo-luminal linear anastomosis (ELLA) surgeries. A stapler to reduce surgical trauma. A novel safe and easy approach of laparoscopic procedure.
Quick test for STROKE risk diagnosis
Aran JM (IDIBELL)
Vulnerable atherothrombotic plaque identification using blood circulating miRNA biomarkers. Point-of-Care microfluidics paperbased analytical device (μPADs) integration (in co-development with Paperdrop Diagnostics S.L.).
Predictive Drug-companion Diagnostic Test for Cancer Therapeutic Resistance
Casanovas O (IDIBELL, ICO)
New predictive drug companion biomarker. NCE for Tumors AA-resistant treatment. In Vitro test for diagnosis, prognosis & prediction of response to cancer treatment.
New facial paralysis rehabilitation software
Montesinos N (HUB)
A real-time software to facial paralysis patients rehabilitation. An improvement of the existing mirror therapy.
Diagnostic test for azoospermia origin
Larriba S (IDIBELL)
Non-invasive azoospermia biomarkers & Kit development. High sensitivity and specificity (>90%). Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.
A web-based platform for the identification of fronto-subcortical connectivity disruptions of brain disorders
Soriano, C (IDIBELL)
Easy-to-use web-based platform to identify biomarkers. Specific neuropsychiatric symptoms-guided brain disorder identification. First diagnosis for effective treatment selection.
A new method to reduce the side effects of Ocular Brachytherapy
LORENZO D (HUB), CAMINAL JM (HUB)
This nanotechnology reduces the radiation dose for an effective treatment. Increasing the array of tumors capable to treat by standard. Brachytherapy.
Companion diagnostic for cutaneous and uveal melanoma
Fabra A (IDIBELL), Ferreres JR (HUB), Caminal JM (HUB)
Prognostic biomarker for cutaneous and uveal melanoma. Combination therapy for metastatic melanoma. Inhibition of metastasis and survival of cancer Stem Cells.
Biosensor-Based Video Game Complementary Tool For Gambling And Eating Disorders Treatment
F. Fernández-Aranda (HUB), Z. Agüera (HUB), S. Jimenez (HUB)
Biosensor-based Video Game. Mobile/tablet device app development. Improvement of impulsivity in patients with gambling and eating disorders.
Virtual therapeutic communities in cancer to facilitate the construction of healthy experiences
C.Ochoa (IDIBELL/ICO) Oncommun – ICOnnecta’t is a flexible, scaled and integrated e-Health educational and psychosocial services program that guarantees correct screening, monitoring and support in health education, adherence to treatments, and the provision of emotional care and psychosocial cancer quality.
A flexible, scaled and integrated e-Health educational and psychosocial services program that guarantees correct screening, monitoring and support in health education, adherence to treatments, and the provision of emotional care and psychosocial cancer quality.